FibroGen Inc reports results for the quarter ended September 30 - Earnings Summary

Kyntra Bio

12/11/2024 23:28

* FibroGen Inc  FGEN.OQ  reported a quarterly adjusted loss
of 17
cents​​ per share for the quarter ended September 30, higher
than the same quarter last year, when the company reported EPS
of -52 cents.  The mean expectation of two analysts for the
quarter was for a loss of 30 cents per share. Wall Street
expected results to range from -38 cents to -23 cents per share.
    * Revenue rose 15.4% to $46.33 million from a year ago;
analysts
expected $34.76 million. 
    * FibroGen Inc's reported EPS for the quarter was a loss
of 17
cents​.
    * The company reported a quarterly loss of $17.08 million.
    * FibroGen Inc shares had fallen by 15.2% this quarter and
lost 61.8% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 1
"hold" and 1 "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is  "sell."

Wall Street's median 12-month price target for FibroGen Inc is
$0.60 
This summary was machine generated from LSEG data November 12 at
11:27 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -0.30          -0.17          Beat
 Jun. 30 2024      -0.32          -0.16          Beat
 Mar. 31 2024      -0.42          -0.33          Beat
 Dec. 31 2023      -0.42          -0.57          Missed